Reischig T,Opatrny JK,Treska V,et al.Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients[J].Kidney Blood Press Res,2005,28(4):218-225.
[3]
Ishida JH,Patel A,Mehta AK,et al.Phase 2Randomized,Double-Blind,Placebo-Controlled Trial of RG7667,a Combination Monoclonal Antibody,for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients[J].Antimicrob Agents Chemother,2017,61(2):e01794-e01716.
[4]
Aguado JM,Gil VS.Prophylaxis of cytomegalovirus infection in renal transplantation[J].Enferm Infecc Microbiol Clin,2011,29Suppl 6:38-41.
[5]
Stern M,Hirsch H,Cusini A,et al.Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment[J].Transplantation,2014,98(9):1 013-1 018.
[6]
Prichard MN,Kern ER.The search for new therapies for Human Cytomegalovirus Infections[J].Virus Research,2011,157(2):212-221.
[7]
Jin ZK,Xu CX,Tian PX,et al.Impact of HLA-G 14-bp polymorphism on acute rejection and cytomegalovirus infection in kidney transplant recipients from northwestern China[J].Transplant Immunology,2012,27(2-3):69-74.
[8]
Said T,Nampoory MR,Pacsa AS,et al.Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients[J].Transplant Proc,2007,39(4):997-999.
[9]
Kacer M,Kielberger L,Bouda M,et al.Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus:an economic perspective[J].Transpl Infect Dis,2015,17(3):334-341.
[10]
Kotton CN,Kumar D,Caliendo AM,et al.International consensus guidelines on the management of cytomegalovirus in solid organ transplantation[J].Transplantation,2010,89(7):779-795.
[11]
Camacho-Gonzalez AF,Gutman J,Hymes LC,et al.24weeks of valganciclovir prophylaxis in children after renal transplantation:a 4-year experience[J].Transplantation,2011,91(2):245-250.
[12]
Kir O,Zeytinoˇglu A,Arda B,et al.Impact of Prophylaxis vs Pre-emptive Approach for Cytomegalovirus Infection in Kidney Transplant Recipients[J].Transplant Proc,2017,49(3):537-540.
[13]
Eshraghi H,Hekmat R.Which CMV viral load threshold should be defined as CMV infection in kidney transplant patients[J]?Transplant Proc,2015,47(4):1 136-1 139.
[14]
Humar A,Snydman D.Cytomegalovirus in solid organ transplant recipients[J].Am J Transplant,2009,9Suppl 4:S78-S86.
[15]
van der Beek MT,Berger SP,Vossen AC,et al.Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation:comparison of treatment failure and antiviral resistance[J].Transplantation,2010,89(3):320-326.
Kawalec P,Holko P,Szkultecka-Debek M,et al.[The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200days after kidney transplantation][J].Pol Merkur Lekarski,2013,34(204):332-338.
[18]
Kawalec P,Szkultecka-Debek M,Maks J,et al.Clinical efficacy and safety of prolonged use of the valganciclovir for the treatment of cytomegalovirus disease in patients after kidney transplantation[J].Pol Merkur Lekarski,2013,35(205):10-13.
[19]
Krishnan A,Zhou W,Lacey SF,et al.Programmed death-1receptor and interleukin-10in liver transplant recipients at high risk for late cytomegalovirus disease[J].Transpl Infect Dis,2010,12(4):363-370.
[20]
Pavlopoulou ID,Syriopoulou VP,Chelioti H,et al.A comparative randomised study of valacyclovir vs.oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients[J].Clin Microbiol Infect,2005,11(9):736-743.
[21]
Reischig T,Kacer M,Jindra P,et al.Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation[J].Clin J Am Soc Nephrol,2015,10(2):294-304.
[22]
Tu PT,Shu KH,Cheng CH,et al.Universal valganciclovir prophylaxis significantly reduces episodes of first-year cytomegalovirus disease and biopsy-proven acute rejection in kidney transplant recipients[J].Transplant Proc,2014,46(2):574-577.
[23]
Reischig T,Hribova P,Jindra P,et al.Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation[J].J Am Soc Nephrol,2012,23(9):1 588-1 597.
[24]
王垒.肾移植术后巨细胞病毒感染的早期诊断[J].肾脏病与透析肾移植杂志,2016,25(3):286-290.Wang L.Early diagnostics of cytomegalovirus infection after kidney transplantation[J].Chinese Journal of Nephrology,Dialysis&Transplantation,2016,25(3):286-290.
[25]
Limaye AP,La Rosa C,Longmate J,et al.Plasma IL-10Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease,in High Risk Solid Kidney and Liver Transplant Recipients[J].Transplantation,2016,100(1):210-216.
[26]
Heldenbrand S,Li C,Cross RP,et al.Multicenter evaluation of efficacy and safety of low-dose versus highdose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive(D+/R+)renal transplant recipients[J].Transpl Infect Dis,2016,18(6):904-912.
Posadas SM,Taber DJ,Chua E,et al.Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation[J].Transpl Infect Dis,2013,15(6):551-558.
[30]
Villeneuve D,Brothers A,Harvey E,et al.Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients[J].Pediatr Transplant,2013,17(1):80-85.
[31]
Kaul DR,Stoelben S,Cober E,et al.First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246[J].Am J Transplant,2011,11(5):1 079-1 084.
[32]
Hashim F,Gregg JA,Dharnidharka VR.Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation[J].Open Urol Nephrol J,2014,7(Suppl 2M7):152-157.
[33]
Boillat BN,Pascual M,Venetz JP,et al.Impact of a preemptive strategy after 3months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients[J].Transplantation,2011,91(2):251-255.
[34]
Santos CA,Brennan DC,Saeed MJ,et al.Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage[J].Clin Transplant,2016,30(4):435-444.
[35]
Requi珘ao-Moura LR,deMatos AC,Pacheco-Silva A.Cytomegalovirus infection in renal transplantation:clinical aspects,management and the perspectives[J].Einstein,2015,13(1):142-148.
[36]
杨典东,张智宇,吴吉涛,et al.缬更昔洛韦与更昔洛韦在肾移植后预防和减少巨细胞病毒感染发生率的比较[J].中华器官移植杂志,2014,35(8):507-508.Yang DD,Zhang ZY,Wu JT,et al.Comparison between valganciclovir and ganciclovir in the prevention and decreasing of cytomegalovirus infection incidence rate after renal transplantation[J].Chin J Organ Transplant,2014,35(8):507-508.
[37]
Gabardi S,Asipenko N,Fleming J,et al.Evaluation of Low-Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients[J].Transplantation,2015,99(7):1 499-1 505.
